Sonodynamic and Acoustically Responsive Nanodrug Delivery System: Cancer Application DOI Creative Commons
Yong‐Gyu Jeong, Joo‐Hwan Park, Dongwoo Khang

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 11767 - 11788

Published: Nov. 1, 2024

The advent of acoustically responsive nanodrugs that are specifically optimized for sonodynamic therapy (SDT) is a novel approach clinical applications. Examining the therapeutic applications sono-responsive drug delivery systems, understanding their dynamic response to acoustic stimuli, and crucial role in enhancing targeted intriguing issues current cancer treatment. Specifically, suggested review covers SDT, modality enhances cytotoxic activity specific compounds (sonosensitizers) using ultrasound (US). Notably, SDT offers significant advantages treatment by utilizing US energy precisely target activate sonosensitizers toward deep-seated malignant sites. potential mechanisms underlying involve generation radicals from sonosensitizers, physical disruption cell membranes, enhanced transport into cells via US-assisted sonoporation. In particular, emerging as promising noninvasive, site-directed elimination solid tumors. Given complexity diversity tumors, many studies have explored integration with other treatments enhance overall efficacy. This trend has paved way SDT-based multimodal synergistic therapies, including sonophototherapy, sonoimmunotherapy, sonochemotherapy. Representative these approaches comprehensively presented, detailed discussion mechanisms. Additionally, application audible sound waves biological systems explored, highlighting influence cellular processes outcomes. Audible can modulate enzyme activities affect behavior, providing avenues use sound-based techniques medical highlights challenges prospects development nanomedicines this rapidly evolving research field. anticipated growth promises significantly improve precision

Language: Английский

Role of liposomes in chemoimmunotherapy of Breast cancer DOI

Fatemeh Attarian,

Ghazaleh Hatamian,

Shamim Nosrati

et al.

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 43

Published: Feb. 19, 2025

In the dynamic arena of cancer therapeutics, chemoimmunotherapy has shown tremendous promise, especially for aggressive forms breast like triple-negative (TNBC). This review delves into significant role liposomes in enhancing effectiveness by leveraging cancer-specific mechanisms such as induction immunogenic cell death (ICD), reprogramming tumor microenvironment (TME), and enabling sequential drug release. We examine innovative dual-targeting that capitalize on heterogeneity, well pH-sensitive formulations offer improved control over delivery. Unlike prior analyses, this directly links advancements preclinical research-such PAMAM dendrimer-based nanoplatforms RGD-decorated liposomes-to clinical trial results, highlighting their potential to revolutionize TNBC treatment strategies. Additionally, we address ongoing challenges related scalability, toxicity, regulatory compliance, propose future directions personalized, immune-focused nanomedicine. work not only synthesizes latest research but also offers a framework translating liposomal from laboratory practice.

Language: Английский

Citations

0
Targeting regulated cell death: Apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity DOI
Ziyu Guo,

Yihuang Liu,

Danyao Chen

et al.

Journal of Translational Internal Medicine, Journal Year: 2025, Volume and Issue: 13(1), P. 10 - 32

Published: Feb. 1, 2025

In the evolving landscape of cancer treatment, strategic manipulation regulated cell death (RCD) pathways has emerged as a crucial component effective anti-tumor immunity. Evidence suggests that tumor cells undergoing RCD can modify immunogenicity microenvironment (TME), potentially enhancing its ability to suppress progression and metastasis. this review, we first explore mechanisms apoptosis, necroptosis, pyroptosis, ferroptosis, cuproptosis, along with crosstalk between these modalities. We then discuss how processes activate antigen-presenting cells, facilitate cross-priming CD8+ T trigger immune responses, highlighting complex effects novel forms on TME biology. Furthermore, summarize potential drugs nanoparticles induce or inhibit emerging their therapeutic roles in treatment. Finally, put forward existing challenges future prospects for targeting anti-cancer Overall, review enhances our understanding molecular biological impacts RCD-based therapies, providing new perspectives strategies

Language: Английский

Citations

0
Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products DOI
Lele Zhang,

Du-Juan Zhang,

Jia-Xin Shi

et al.

Phytomedicine, Journal Year: 2024, Volume and Issue: 132, P. 155828 - 155828

Published: June 13, 2024

Language: Английский

Citations

4
A new paradigm for cancer immunotherapy: targeting immunogenic cell death-related noncoding RNA DOI Creative Commons

Guojuan Sun,

Ling He

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 23, 2025

Cancer immunotherapy has shown significant potential in treating several malignancies by stimulating the host immune system to recognize and attack cancer cells. Immunogenic cell death (ICD) can amplify antitumor responses reverse immunosuppressive tumor microenvironment, thus increasing sensitivity of immunotherapy. In recent years, noncoding RNAs (ncRNAs) have emerged as key regulatory factors ICD oncologic immunity. Accordingly, ICD-related ncRNAs hold promise novel therapeutic targets for optimizing efficacy However, immunomodulatory properties not yet been comprehensively summarized. Hence, we summarize current knowledge on involved their roles this review. It deepens our understanding associated with provides a new strategy enhance specifically targeting ncRNAs.

Language: Английский

Citations

0
Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors DOI Open Access
Valeria Lucarini,

Ombretta Melaiu,

Paula Gragera

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1613 - 1613

Published: Feb. 14, 2025

The combination of chemotherapeutic agents with immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment. However, its success is often limited by insufficient priming in certain tumors, including pediatric malignancies. In this report, we explore clinical trials currently investigating the use immunogenic cell death (ICD)-inducing chemotherapies ICIs for both adult and cancers. Given data available focused on recent preclinical studies evaluating efficacy these combinations neuroblastoma (NB). Finally, to address gap, propose an innovative strategy assess impact ICD-inducing antitumor responses NB. Using tumor spheroids derived from a transgenic NB mouse model, validated our previous vivo findings concerning how anthracyclines, specifically mitoxantrone doxorubicin, significantly enhance MHC class I surface expression, stimulate IFNγ granzyme B production CD8+ T cells NK cells, promote recruitment. Importantly, anthracyclines also upregulated PD-L1 expression spheroids. This screening platform yielded results similar findings, demonstrating that doxorubicin are most potent immunomodulatory These suggest creation libraries ICD inducers be tested could reduce number vivo, line principles 3Rs. Furthermore, highlight potential chemo-immunotherapy regimens counteract immunosuppressive microenvironment NB, paving way improved therapeutic strategies They provide compelling evidence support further investigations outcomes children

Language: Английский

Citations

0
Microbiome-mediated immune modulation in tumor microenvironment DOI
John O. Richards,

Eleanor L. Davis,

L. Shakila

et al.

International review of cell and molecular biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Metallodrugs: From mere cytotoxic agents to immune modulators and checkpoint inhibitors DOI
Muhammad Nafees, Muhammad Hanif,

Piaoping Yang

et al.

Chinese Chemical Letters, Journal Year: 2025, Volume and Issue: unknown, P. 111013 - 111013

Published: Feb. 1, 2025

Language: Английский

Citations

0
The Dual Role of Chaperone-mediated Autophagy in the Response and Resistance to Cancer Immunotherapy DOI Creative Commons
Mohammadreza Saberiyan,

Sarah Gholami,

Mahsa Ejlalidiz

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: 210, P. 104700 - 104700

Published: March 12, 2025

Cancer immunotherapy has become a revolutionary strategy in oncology, utilizing the host immune system to fight malignancies. Notwithstanding major progress, obstacles such as evasion by tumors and development of resistance still remain. This manuscript examines function chaperone-mediated autophagy (CMA) cancer biology, focusing on its effects tumor response resistance. CMA is selective degradation mechanism for cytosolic proteins, which crucial sustaining cellular homeostasis regulating responses. By degrading specific can either facilitate progression stressful conditions, or promote suppression removing oncogenic factors. double-edged sword highlights complexity possible effect treatment results. Here we clarify molecular mechanisms regulate role therapeutic target improving effectiveness immunotherapy.

Language: Английский

Citations

0
Optimization of Cancer Immunotherapy Through Synergistic Enhancement of Immunogenic Cell Death by Multifunctional Nanobioreactors Combined with Immune Checkpoint Inhibitors DOI
Hui Zhang, Chunyu Qu, Ziqing Yang

et al.

ACS Applied Nano Materials, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Language: Английский

Citations

0
Advancing the understanding of the role of apoptosis in lung cancer immunotherapy: Global research trends, key themes, and emerging frontiers DOI Creative Commons

Chunjian Zuo,

Jie Tian

Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)

Published: April 5, 2025

Apoptosis is vital for improving the efficacy of lung cancer (LC) immunotherapy by targeting cell elimination. Despite its importance, there a lack comprehensive bibliometric studies analyzing global research on apoptosis in LC immunotherapy. This analysis aims to address this gap highlighting key trends, contributors, and future directions. A total 969 publications from 1996 2024 were extracted Web Science Core Collection. Analysis was conducted using VOSviewer, CiteSpace, R package 'bibliometrix.' The study included contributions 6,894 researchers across 1,469 institutions 61 countries, with published 356 journals. volume has steadily increased, led China United States, Sichuan University as top contributor. journal Cancers most articles, while Cancer Research had highest co-citations. Yu-Quan Wei leading author, Jemal, A. frequently co-cited. Key themes include "cell death mechanisms," "immune regulation," "combination therapies," "gene nanomedicine applications," "traditional Chinese medicine (TCM)." Future likely focus "coordinated regulation multiple pathways," "modulation tumor immune microenvironment," "optimization combination "novel strategies gene "integration TCM" personalized treatment. first role immunotherapy, providing an landscape patterns emerging therapeutic strategies. findings offer insights guide optimize treatment approaches.

Language: Английский

Citations

0